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Kawasaki disease (KD) is an acute-onset systemic vasculitis of medium-sized vessels
that mostly affects infants and toddlers. Globally, it is the most common form of
childhood primary vasculitis. Delayed diagnosis and treatment results in coronary artery
aneurysms in up to 25% of all affected individuals. Thus, KD is the most common
acquired heart disease in developed countries. Here, the current understanding of
clinical presentations, pathophysiological concepts, disease-associated complications,
and available pharmaceutical treatment is provided and discussed in the context of
available literature.
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BACKGROUND
Kawasaki disease (KD) is a systemic vasculitis mostly affecting medium-sized arteries. Main
symptoms include fever, conjunctivitis, skin and mucous membrane affection, and cervical
lymphadenopahty. The name KD goes back to the detailed description of 50 children experiencing
this form of vasculitis by Tomakisu Kawasaki in 1967 (1). Generally, inflammatory changes to
arterial vessels of all body regions can be present, however, coronary arteries are most commonly
affected (2). In cases of delayed treatment, missed diagnosis, or in treatment refractory cases,
aneurysms can result and cause severe sequelae, including cardiac infarctions (Figure 1, Box 1).
Globally, KD is the most common primary childhood vasculitis, in central Europe and North
America it is the secondmost common form (after Henoch Schoenlein Purpura; HSP). To date, KD
is considered the most common acquired cardiac condition in childhood in developed countries
(3, 4).
EPIDEMIOLOGY
Though reported globally and not sparing any ethnicities, KD is most common in Japan. Incidence
in Japan is approximately 240/100.000 children under 4 years-of-age (5). In North America (USA),
KD incidence ranges around 17/100.000 (6). In Caucasian populations incidences range around
9/100.000 (7, 8). Approximately 85% of KD patients are younger than 5 years with an average of
approximately 2 years. However, cases in younger and older individuals have been reported (9).
Young patients under 12 months have an increased risk for the development of coronary artery
aneurysms (up to 60% if untreated). This is particularly concerning, since disease presentation in
this young age group is frequently “incomplete” and patients fail to be diagnosed correctly (8, 10).
ETIOLOGY AND PATHOGENESIS
The etiology of KD is not known. The presence of familial clusters and increased incidence in Asian
populations indicate the presence of a genetic component (5, 11). Associations with genetic variants
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FIGURE 1 | Coronary artery aneurysms. (A) Cardial ultrasound of a 3 year old male showing right coronary vessel with aneurysm, and (B) classical coronary
angiography in a 2 year old male unveiled giant aneurysm of the left coronay vessel.
Box 1 | Clinical course of an initally undiagnosed patient with KD.
A 3 year-old Caucasian boy exhibited fevers over 7 days (up to 40◦C). In
the presence of generalized exanthema and tonsillopharyngitis, the diagnosis
Scarlet fever was made, and he was treated with aminopenicilline. During
the clinical course, reddish swelling of the palms and plants developed.
On day 7, the patient was admitted to a small community hospital
(with no pediatric rheumatology service). On the day of admission, one
brief febrile episode was recorded (38.3◦C). On subsequent days, the
boy remained afebrile. At admission, reduced general condition, no skin
changes, but purulent pharyngitis were recorded. Symmetric conjunctivitis
and cervical lymphadenopathy were seen. Bloodwork unveiled elevated
CRP levels of 116.6 mg/l and mild thrombocytosis of 464.000/µl (at
discharge: 697.000/µl). The patient was diagnosed with tonsillopharyngitis
and discharged after several days in good general condition. Cardiac
ultrasound was not performed.
Two months after the event, the boy was admitted to the pediatric intensive
care unit in cardiac shock. Cardiac ultrasound and subsequent angiography
unveiled coronary artery aneurysms and thromboembolic vessel occlusion.
Because of persistent cardiac failure, cardiac transplantation was necessary
and successfully performed.
have been established in various populations (Table 1). Genetic
variants in the transforming growth factor (TGF) pathway
(TGFβ2, TGFβR2, SMAD3) are associated with an increased risk
for the development of coronary aneurysms in European KD
patients (15, 16). Taken together, it appears that genetic risk
for the development of KD and coronary aneurysms may be
influenced by variants in several genes that link to immunological
pathways. Genetic susceptibility may vary between populations
which may explain increased incidences in Asian populations.
Seasonal and regional clusters, and reported associations
with wind directions suggest exogenous factors contributing
to disease expression in genetically predisposed individuals
(17, 18). It has been suggested that infectious agents with
low transmission rates or penetrance may cause subclinical
disease in many individuals, while causing KD in genetically
predisposed children. One line of research suggests the presence
of RNA virus infections in KD patients (19, 20). Cytoplasmic
inclusion bodies in bronchial epithelia from KD patients contain
RNA that could deliver a disease-associated pathogen. However,
intensive efforts to characterize failed to deliver an explanation.
Furthermore, attempts to identify disease-causing pathogens
from patients‘blood or endothelial walls have not been successful
(21).
Another previously considered explanation was the presence
of a superantigen response to endothelial cells (22). The fact that
bacterial strains, particularly Streptococcus and Staphylococcus
spp. produce superantigens supported this hypothesis in light of
seasonal clusters in winter. Nevertheless, the only human disease
clearly demonstrated to be caused by superantigen exposure to
date is toxic shock syndrome (23).
Activation of innate immune cells is an early event in KD and
reflected by the increased numbers of neutrophilic granulocytes
in the periphery and increased expression and release of pro-
inflammatory cytokines IL-1β, IL-6, and TNF-α (19). Over the
natural course of KD, effector memory and central memory
T cells expand in numbers during the acute phase of KD,
while effector memory T cells reduce in numbers during the
covalescent phase. This indicated activation of the adaptive
immune system during the course of KD (24). Furthermore, IVIG
treatment coincides with increased numbers of regulatory T cells,
which may be central during the termination of inflammatory
responses in KD (25). Whether the emergence of effector T
cells in the peripheral blood during the acute phase and the
association of cessation of fever after IVIG administration and
increased numbers of regulatory T cells during the covalescent
phase are indicative of previosuly discussed pathogens or a result
of global immune activation in response to initially prevalent
innate immune mechanisms remains to be determined.
Taken together, genetic variants predispose to the
development of KD. Additional factors appear to be necessary
for disease expression. Whether KD is triggered by infectious
agents in genetically predisposed individuals or whether it is
a genetically complex primary autoinflammmatory disorder
currently remains an unanswered question.
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CLINICAL PRESENTATION AND
DIAGNOSIS
In all cases, KD begins with acute-onset high fever, reduced
general condition and frequently reduced cooperativity of
children which can complicate physical examination. Further
symptoms include generalized polymorphic exanthema
(>90%), palmoplantar erythema (80%), symmetric non
purulent conjunctivitis (80–90%), usually unilateral cervical
lymphadenopathy (>1.5 cm; 50%), and mucosal enanthema with
red and/or chapped lips (80–90%) (26) (Figure 2). Additional
symptoms include anterior uveitis that can occur in up to 80%
of patients (27), and arthritis of small joints (in up to 15%)
(28). Later, after several weeks, periungual and/or perianal
desquamation, and nail anomalies (Beau lines) can occur (29)
(Figure 3). In such cases, the diagnosis can be made based on
clinical criteria (Box 2).
Criteria for the diagnosis of KD are provided in Box 2 and
Figure 2.
As also true in other autoimmune/inflammatory conditions,
aforementioned definitions do not cover all patients with
KD. Up to 36% of patients do not fulfill the diagnostic
criteria for KD and can therefore easily be missed.
Unfortunately, this group of patients with “incomplete
KD” exhibit a particularly high risk for the development
of complications, particularly coronary artery aneurysms
(34, 35). Particularly young patients with disease-onset in
the first 12 months of life delevop these incomplete pictures
(36).
For patients with suspected incomplete KD, McCrindle et al.
(4) suggested diagnostic pathways (Figure 4). Of note, some
patients may show atypical clinical findings like exsudative
pharyngitis or exsudative conjunctivitis (see Box 1) which
make throroughly repetive clinical and laboratory examination
TABLE 1 | Genetic associations in KD.
KD Gene association Population Predicted effects References
BLK Japanese, Taiwanese, Korean Increased B cell receptor signaling (12)
CASP3 Japanese, Taiwanese, Korean, Chinese, white
Americans
Reduced gene expression with effects on cell death (13)
CD40 Japanese, Taiwanese, Korean Risk allele with increased gene expression, subsequently increased immune
activation
(12)
FCGR2A Europeans, Taiwanese, Koreans, Chinese Reduced binding affinity of low-affinity FCG receptor 2A with effects of
immune complex clearance
(14)
HLA class II Japanese, Taiwanese, Korean Immune activation through antigen presentation (12)
IPTKC Japanese, Taiwanese, Korean, Chinese, white
Americans
Negative regulator of NFAT signaling pathway; risk allele results in icnreased
NFAT signaling
(15)
BLK, Gene encoding for the tyrosine-protein kinase BLK also known as B lymphocyte kinase; CASP3, Caspase 3 gene; CD40, Cluster of differentiation 40 gene; FCGR2A, Gene
encoding for the low affinity immunoglobulin gamma Fc region receptor 2A; HLA, human leukocyte antigen (HLA); IPTKC, Gene encoding for the inositol 1,4,5-trisphosphate 3-kinase C.
FIGURE 2 | Clinical criteria in KD. (A) Bilateral non-purulent conjunctivitis (80–90%), (B) changes to oropharyngeal mucous membranes, including injected and/or
fissured lips, strawberry tongue (80–90%), (C) Palmar and/or (D) plantar erythema (E) polymorphous exanthema, primarily truncal, not vesicular (>90%), and (F,
G) cervical lymphadenopathy (>1.5 cm) (50%). (G) Ultrasound of enlarged cervical lymph nodes with increased perfusion. (H) Periungual desquamation (in
covalescent phase) (80%), (I) Beau lines.
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FIGURE 3 | Phases of KD are characterised by variable clinical symptoms. Kawasaki disease reconstitutes a systemic inflammatory disorder with an acute, subacute,
and convalescent/recovery phases. Clinical symptoms vary over the course of disease. Classical temporal characteristics are typical of the course of the disease
[Figure modified from (23)].
Box 2 | Clinical criteria for the diagnosis of “classical” KD (30–33).
Fever of unknown origin for ≥5 days plus 4 of the following if not explained
by another condition. The diagnosis can also be made on day 4 day in
the presence of ≥4 principal clinical criteria, particularly when redness and
swelling of the hands and feet are present)
• Bilateral Conjunctivitis (80–90%)
• Changes to oropharyngeal mucous membranes, including injected and/or
fissured lips, strawberry tongue and enanthema (80–90%)
• Palmar and/or plantar erythema and/or periungual desquamation (in
covalescent phase) (80%)
• Polymorphous exanthema, primarily truncal, not vesicular (>90%)
• Cervical lymphadenopathy (at least one lymph node >1.5cm) (50%)
mandatory for not missing the diagnosis. For these cases the term
“atypical KD” is recommended (37).
Most severe complications usually involve the heart. In the
acute phase, a majority of patients exhibit clinically inapparent
myocarditis. Arrythmia and cardiac failure, however, are
uncommon in this phase (38). Additional organ manifestations
include pancreatitis, urethritis, facial palsy and/or macrophage
activation syndrome. Ophthalmologic exams should be
performed, since anterior uveitis can occurr in up to 80% of
KD patients. Non-specific symptoms, such as nausea, diarrhea,
abdominal pain (61%), cough and rhinitis (35%) may be present
and can delay making the correct diagnosis (28, 37) (Figure 5).
Laboratory investigations and imaging techniques can help
to make the correct diagnosis (particularly in incomplete
KD) and to exclude important differential diagnoses.
Laboratory investigations usually provide evidence for systemic
inflammation. Within the first 10 days, almost 80% of KD
patients exhibit elevated CRP levels (≥30 mg/l) and ESR
(≥40/h). Some patients exhibit elevated liver enzymes (ALT
≥50 U/l), hypoproteinemia and reduced plasma lipid levels,
elevated cholestasis parameters (GGT ≥40, hyperbilirubinemia),
thrombocytosis (≥450.00/µl), leukocytosis (≥15.000/µl), and/or
anemia (Figure 4). In cerebrospinal fluid pleocytosis can be seen
in more than 1/3 of KD patients (26, 39). Elevated NT-proBNP
(N-terminal pro-brain natriuretuc peptide) levels correlate with
increased risk for elevated coronary arteries and may be used
as predictive biomarker in the future (40). Serum electrolytes
should be tested because inadequate ADH secretion can result in
hyponatremia (Figure 5, Box 3) (37).
Cardiac ultrasound is required in suspected KD. Though
coronary aneurysms usually develop after several weeks
(Figures 1, 3), pericardial effusions or coronary arteries with
pronounced vessel walls can be detected early in disease (44, 45).
Abdominal sonography can detect intraabdominal effusions and
biliary hydrops (37).
DIFFERENTIAL DIAGNOSES
Generally, fever without focus over several days in preschool
children should trigger the differential diagnosis KD (Box 2).
Diagnosis can be complicated by incomplete or atypical KD.
The most common and important differential diagnosis are viral
infections. Depending on clinical presentations, infections with
Adeno-, Parvo-, Herpes-, and EB-virus need to be considered. In
measles, exanthema and enanthema can look similar to KD. In
Scarlet fever, exanthema, enanthema, cervical lymphadenopathy
resemble symptoms of KD. However, purulent tonsillitis and the
abscence of conjunctivitis in Scarlet fever can help differentiating
the two entities (46). Nevertheless caution is needed to not miss
atypical cases (Box 1).
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FIGURE 4 | Suggested diagnostic algorithm in suspected incomplete KD. While generally following the suggestions of McCrindle et al. (4), the authors feel that
cardiac ultrasound should be performed in all children with fever without focus over ≥5 days and ≥2 clinical criteria for KD or infants with fever without focus ≥7 days
independent of CRP levels at least initially.
FIGURE 5 | Additional symptoms and possible organ involvement in KD.
Other systemic inflammatory conditions can be differential
diagnoses to KD, including systemic juvenile idiopathic arthritis
(sJIA). While discriminating between the two entities can be
difficult, sometimes the absence of conjunctivitis in sJIA can he
helpful.
TREATMENT AND MONITORING
After making the diagnosis KD, timely treatment with
intravenous immunoglobulins is required (IVIG 2g/kg/KG)
(Figure 6). It was demonstrated that IVIG treatment, if
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Box 3 | Controversy about Kobayashi score in non-Asian populations.
The Kobayashi risk score was tested in a small ethnically mixed population
of KD patients the USA. The retrospective analysis delivered high specificity
(87%) but low sensitivity (33%). However, only 3 out of 9 patients could
be included in the statistical analysis (41). Another small study from the UK
delivered specificity of 35%, and sensitivity of 58%. Also this population was
small and only included 59 patients (42). Though patient numbers in the
two available studies were small and predictive impact is therefore limited,
the Kobayashi score failed to identify high risk patients in ethnically mixed
populations.
Recently, data from a population-based survey in Germany (ESPED) in the
years 2013 and 2014 (301 children at diagnosis, 177 children with follow-
up data over 1 year) suggested low prognostic value for the development
of persistent coronary aneurysms (after 1 year) of three available scores:
Kobayashi, Egami and Sano scores (43). Though overall predictive values
were low, scores may be helful to predict courses refractory to IVIG treatment
in individual patients.
applied within the first 10 days of fever, reduces the risk
for the development of coronary aneurysms from 25% to
approximately 5% (48). Furthermore, concommittent treatment
with acetylic acid (ASA) (30-)50(-80) mg/kg/day in 4 daily doses
is recommended and can be tapered to 3–5 mg/kg/day when
patients are afebrile—usually for 48–72 h (49).
Approximately up to 30% of KD patients do not fully respond
to these measures (as defined by persisting fever after 48–72 h).
Unfortunately, these individuals are at an increased risk for
the development of coronary aneurysms (50–53). To identify
these individuals, the Kobayashi score was developed. 2 points
are given for: Hyponatremia (<133 mmol/l), elevated GPT
(>100/µl), ≤4 days of fever before treatment initiation, and
severe neutrophilia (>80%); 1 point is given for: young age
(<12 months), high CRP (>100 mg/l) and low thrombocyte
counts (<300.000/µl). A score of ≥5 correlated with failure
to respond to IVIG alone and with increased risk for the
development of coronary aneurysms in Japanese children (54).
In the same population, oral application of prednisolone until
CRP levels normalized significantly reduced the risk for cornary
aneurysms (55). These positive effects were supported by
a metaanalysis, and none of the included studies suggested
significant side effects of oral corticosteroids (56). Of note,
positive effects of corticosteroid treatment could not be seen
in patients treated with a single i.v. methylprednisolone pulse
(57).
For KD patients of Asian descent, various risk scores were
developed and showed reasonable sensitivity (77–86%) and
specificity (67–86%) for the prediction of IVIG non-response
(54, 58, 59). Conversely, two small retrospective studies in mixed
ethnic populations in the USA and the UK delivered conflicting
results (41, 42) (Box 3).
Based on the observations in two studies in ethnically mixed
populations, the value of Kobayashi and other risk assessment
scores in non-Asian populations remains unclear. In addition to
the aforementioned risk assessment tools, additional associated
factors have been reported and include anemia, elevated lactate
dehydrogenalse (LDH) levels (>560U/µl), hyperbilirubinemia
>0.9mg/l), fever for more than 10 days, male gender, and
incomplete courses (35, 42, 60, 61). Whether a low threshold
for corticosteroid use in non-Asian populations can compensate
for reduced sensitivity of risk scores required to be answered.
In the authors‘institutions, corticosteroids are currently used
at a low threshold in non-Asian KD patients considering the
aforementioned risk factors as a final and reliable score for
all non-Asian KD patients can currently not be provided.
Undoubtedly, all patients with initial cardiac involvement,
associated cardiogenic shock, or macrophage activation should
receive corticosteroid treatment in addition to “standard
treatment” (62).
Several treatment options have been suggested for
treatment of refractory cases, which include additional IVIG,
corticosteroids, cyclosporine A, and cytokine blocking strategies
(63–65). It is worthmentioning that delayed introduction of anti-
inflammatory treatment and subsequently prolonged systemic
inflammation in KD increases the risk to develop complications
(50, 52, 53). Thus, early diagnosis and sufficient treatment are
important steps to prevent treatment refractory clinical courses.
However, if KD patients fail to respond to standard treatment,
either corticosteroids (usually methylprednisolone 20–30 mg/kg
intravenously for 3 days with or without subsequent course
of tapered oral prednisone) or additional IVIG were reported
effective (50, 66, 67). However, beneficial effects were never
studied in a randomized clinical trial.
TNF blocking strategies (Infliximab) showed comparable
efficacy when compared to a second IVIG course (65). In
individual cases, infliximab treatment was associated with
regression of coronary aneurysms (68, 69). However, other
reports failed to detect beneficial effects in the prevention of
coronary aneurysms (70, 71). Furthermore, additional treatment
with infiximab on top of IVIG for induction therapy did
not reduce the risk for cononary aneurysms in a large
randomized prospective study after 5 weeks (72). Taken
together, beneficial effects of infliximab on the prevention
of cornary aneurysms in KD have not been convincingly
documented.
Also, the role of IL-1 blocking strategies has currently
not been established, but promise potential. Studies in mice
suggest that both IL-1α and IL-1β are centrally involved in
the pathophsyiology and development of arterial aneurysms in
KD that is preventable by IL-1 blockade (73, 74). Furthermore,
beneficial effects of IL-1 blockade have been demonstrated in
individual KD cases in humans. A prospective clinical trial
investigating effects of treatment with recombinant IL-1 receptor
antagonis anakinra in KD patients with early coronary artery
involvement (ANAKID trial), however, is not completed yet (75–
77). Another interventional clinical trial, aiming to investigate
efficacy and safety of canakinumab in pediatric patients KD was
withdrawn in 2017.
Calcineurin inhibitors (cyclosporin A, tacrolimus) were
tested in small studies (10 and 28 KD patients) and terminated
fevers in a subset of otherwise treatment resistant cases.
In some cases, calcineurin inhibitor treatment coincided
with regression of pre-existing coronary aneurysms (63, 78).
However, recent observations in mice, indicating exacerbation
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FIGURE 6 | Suggested therapeutic algorithm in KD patients. IVIG, intravenous immunoglobulins; ASA, acetylic acid; MPP, Methylprednisolone i.v. pulse [Modified after
(4, 47)].
of arterial wall aneurysms after calcineurin inhibitor treatment,
together with limited experience in human KD raise concerns
regharding this treatment option (79). Statin treatment
(simvastatin) resulted in significant reduction of CRP
levels and coronary dilation in a very small study (80).
Sucessful use of cyclophosphamide and plasmapheresis have
been reported in individual extremely complicated cases
(81, 82).
Acetylic acid (ASA) has been used in the treatment
of KD for many years. ASA exhibits anti-inflammatory
effects at high doses (50mg/kg/d), and anti-platelet activity
at low doses (3–5mg/kg/d). Regardless of anti-inflammatory
effects, high-dose ASA alone does not reduce the risk
of coronary aneurysms development, and should therefore
only be given in combination with IVIG and potentially
other anti-iflamatory treatment options in KD. Usually, in
central Europe and North America, high dose ASA is
replaced by low-dose ASA (3–5 mg/kg) after fever eradication.
Low-dose ASA should be continued for 6–8 weeks, until
coronary ultrasound excludes coronary changes. If coronary
aneurysms develop, ASA may be continued indefinitely (4).
In the case of large coronary aneurysms, anticoagulant
treatment may be considered and is discussed elsewhere
(83).
In Figure 6 we provide a suggestion for a therapeutic
algorithm based on the available literature, expert opinion, and
personal experience of the authors.
Since arterial anuerysms, particularly coronary aneurysms,
develop within in the first few weeks after the onset of KD,
coronary ultrasound should be performed within and at the
end of this period (4–6 weeks after first treatment) (4, 84).
Other authors consider altered endothelial function in KD a
risk for subsequent coronary disease and recommend “life-style”
counceling in regards to atherosclerosis and cardiac ultrasounds
every 5 years (85). However, this is currently not part of national
or international expert recommendations.
PROGNOSIS
With timely and adequate treatment (IVIG and ASA),
approximately 5% of all KD patients develop arterial aneurysms.
Mortality is approximately 0.1% (86). Since delayed diagnosis
and treatment initiation are associated with treatment refractory
courses and the development of coronary aneurysms, early and
sufficient treatment are a key to sucess (50, 52, 53). Generally,
cardiovascular risk for KD patients without coronary artery
luminal changes is comparable to the general population
(87, 88). For all other patients, the severity of luminal anomalies
and potentially resulting sequelae (myocardiac infarction, etc.)
define the individual risk (4). The risk of relapses in KD is
relatively low, and has been reported 2.9% in Japanese children
(89).
CONCLUSIONS
Kawasaki disease is a clinically defined systemic vasculitis of
mainly medium-sized arteries. Since “incomplete” cases occur,
KD should be considered in pre-school children with fever
without focus. Delayed or missed diagnosis can result in
severe complications, while timely and correct diagnosis and
treatment initiation usually garantee a good prognosis. Risk
assessment scores are available for Asian populations, however,
may miss individual children with increased risk for aneurysm
development in other ethnicities. Thus, a low threshold for
corticosteroid use may be adviseable in non-Asian populations.
Further studies are required and warranted testing effects of
cytokine blocking strategies in KD.
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